Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon May 05, 2022 6:32pm
103 Views
Post# 34660428

RE:RE:RE:RE:RE:New tranche of went thru

RE:RE:RE:RE:RE:New tranche of went thru This list looks like a more accurate list of Insider holdings than the Stockhouse Insider list which I found confusing.  
Andrew and his father's company presently own 7,963,988 shares which is approx. 20.7%.  The most accurate count of shares outstanding I found is 38,530,000. I don't think this includes the latest PP with an additional 8,333,333. 
I don't think the shares Andrew purchased in this last PP have been posted yet.  Would be interesting to see how many he has now. 

I think we all agree that he see's something in this company that will return him a hefty profit at some point.  He also convinced his father and his company to get involved.  That alone must give the rest of us some security that at some point we may see a return on our investment but when is the question.
<< Previous
Bullboard Posts
Next >>